KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Current Deferred Revenue (2017 - 2025)

Historic Current Deferred Revenue for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $1.2 million.

  • Bionano Genomics' Current Deferred Revenue fell 125.52% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 125.52%. This contributed to the annual value of $1.1 million for FY2024, which is 4406.13% up from last year.
  • Latest data reveals that Bionano Genomics reported Current Deferred Revenue of $1.2 million as of Q3 2025, which was down 125.52% from $1.2 million recorded in Q2 2025.
  • Bionano Genomics' Current Deferred Revenue's 5-year high stood at $1.2 million during Q3 2024, with a 5-year trough of $301000.0 in Q1 2021.
  • Moreover, its 5-year median value for Current Deferred Revenue was $1.0 million (2025), whereas its average is $923368.4.
  • In the last 5 years, Bionano Genomics' Current Deferred Revenue surged by 26777.41% in 2022 and then plummeted by 1711.86% in 2023.
  • Bionano Genomics' Current Deferred Revenue (Quarter) stood at $684000.0 in 2021, then rose by 27.34% to $871000.0 in 2022, then decreased by 10.1% to $783000.0 in 2023, then surged by 44.06% to $1.1 million in 2024, then rose by 4.61% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $1.2 million for Q2 2025, and $1.0 million during Q1 2025.